Back to top
more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$148.98 USD

148.98
1,505,545

-3.69 (-2.42%)

Updated Jul 16, 2024 04:00 PM ET

After-Market: $148.88 -0.10 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT

Sarepta (SRPT) Q4 Earnings Beat, DMD Drugs Sales Robust

by Zacks Equity Research

Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the fourth quarter. The company also raises revenue guidance for the year. Stock down in after-market trading.

Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 5.96% and 6.48%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Kinjel Shah headshot

Drug/Biotech Stocks' Q4 Earnings on Mar 1: PRGO, JAZZ & More

by Kinjel Shah

Let us look at five drug/biotech companies, PRGO, JAZZ, HZNP, SRPT and AXSM, which are gearing up for their earnings release.

Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 96.88% and 3.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Addus HomeCare (ADUS) Matches Q4 Earnings Estimates

by Zacks Equity Research

Addus HomeCare (ADUS) delivered earnings and revenue surprises of 0% and 1.67%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Sarepta's (SRPT) DMD Gene Therapy Study Data Fails to Impress

by Zacks Equity Research

Sarepta's (SRPT) DMD gene therapy candidate achieves statistically significant improvement in patients but the data fails to meet market expectations. Stock down.

Apellis (APLS) Up More Than 40% in Past 3 Months: Here's Why

by Zacks Equity Research

Approval of Apellis' (APLS) Empaveli for treating paroxysmal nocturnal hemoglobinuria lends a significant boost to the company's growth prospects. The drug's label expansion studies also hold promise.

Lexicon (LXRX) Submits NDA to the FDA for Cardiovascular Drug

by Zacks Equity Research

Lexicon (LXRX) submits an application to the FDA seeking approval for sotagliflozin to lower the risk of cardiovascular death and hospitalization and urgent visits for heart failure in adult patients.

Blueprint Medicines (BPMC) Up 24.8% in Past 6 Months: Here's Why

by Zacks Equity Research

Blueprint Medicines' (BPMC) Ayvakit, approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. Other pipeline candidates are also progressing well.

Kodiak Sciences (KOD) Focuses on Developing Eye Candidate KSI-301

by Zacks Equity Research

Kodiak Sciences (KOD) progresses well with the development of its lead candidate, KSI-301, for treating various retinal vascular diseases. Stiff competition in the target market remains a woe.

Kiniksa (KNSA) COVID-19 Study for ARDS Fails to Meet Main Goal

by Zacks Equity Research

Kiniksa (KNSA) reports that the phase III portion of mavrilimumab???s phase II/III study for COVID-related ARDS did not meet the primary efficacy endpoint.

Palatin (PTN) Begins Phase III Study For Dry Eye Disease

by Zacks Equity Research

Palatin (PTN) commences the pivotal phase III study evaluating PL9643 for the treatment of dry eye disease. Top-line data from the same is expected in the second half of 2022.

Goldman Sachs, GameStop, Repligen, Sarepta Therapeutics and BeiGene highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Goldman Sachs, GameStop, Repligen, Sarepta Therapeutics and BeiGene highlighted as Zacks Bull and Bear of the Day

Ekta Bagri headshot

3 Biotech Stocks Worth Adding to Your Portfolio Next Year

by Ekta Bagri

Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.

The Zacks Analyst Blog Highlights: Daqo New Energy, Pinterest, Sarepta Therapeutics, JOYY and Chindata Group

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Daqo New Energy, Pinterest, Sarepta Therapeutics, JOYY and Chindata Group

Lilly's (LLY) Eczema Study on Lebrikizumab Combo Meets Goal

by Zacks Equity Research

Eli Lilly's (LLY) pivotal phase III study on lebrikizumab in combination with topical corticosteroids meets the primary and key secondary endpoints.

Novartis (NVS) to Buy Gyroscope, Submits Herceptin Biosimilar to EMA

by Zacks Equity Research

Novartis (NVS) is set to acquire ocular gene therapy company Gyroscope Therapeutic. Generic arm Sandoz submits a marketing authorization application for a proposed biosimilar of Herceptin.

ACADIA (ACAD) Up on Resubmission Plan for Nuplazid sNDA to FDA

by Zacks Equity Research

ACADIA (ACAD) to resubmit sNDA for Nuplazid (pimavanserin) to the FDA for treating hallucinations and delusions associated with dementia focused on Alzheimer's disease psychosis. Shares rise.

Sanofi (SNY) to Acquire Amunix, Boost Immuno-oncology Pipeline

by Zacks Equity Research

Sanofi (SNY) inks a deal to acquire privately-held Amunix Pharmaceuticals, which will add potentially transformative cancer therapies to its immuno-oncology pipeline.

Novartis (NVS) Collaborates With BeiGene for Oncology Drug

by Zacks Equity Research

Novartis (NVS) signs collaboration and license agreement with BeiGene for ociperlimab (BGB-A1217), expanding research and development activities in immuno-oncology.

Gilead's (GILD) Veklury Gets EC Nod for Use in Early COVID-19

by Zacks Equity Research

Gilead's (GILD) Veklury can now be used in the EU at the early stages of COVID-19 to help prevent disease progression in high-risk patients.

Anindya Barman headshot

These 5 Loser Stocks of 2021 Could be Big Winners in 2022

by Anindya Barman

The momentum in the equity markets is expected to stay on firm-footing in 2022. DQ, PINS, SRPT, YY and CD have a chance to outperform next year.

Seagen (SGEN) Gets Positive CHMP Opinion for Bladder Cancer Drug

by Zacks Equity Research

The CHMP gives a positive opinion on, and recommends approval to Seagen's (SGEN) Padcev as a monotherapy for treating adult patients with locally advanced/metastatic urothelial cancer.